Loading clinical trials...
Loading clinical trials...
Eltrombopag for the Management of Thrombocytopenia Associated With Tyrosine Kinase Therapy in Patients With Chronic Myeloid Leukemia (CML) and Myelofibrosis (MF)
Conditions
Interventions
Eltrombopag Olamine
Locations
1
United States
M D Anderson Cancer Center
Houston, Texas, United States
Start Date
January 13, 2012
Primary Completion Date
January 3, 2022
Completion Date
January 3, 2022
Last Updated
September 26, 2023
NCT02689440
NCT03147612
NCT00254423
NCT02220985
NCT00719888
NCT04526795
Lead Sponsor
M.D. Anderson Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions